---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-079342"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:09:13.762020+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q4 GAAP net loss $22.8M ($0.42/sh), completes $150M offering, cash runway to 1H 2028

## Summary
- Cash $48.3M at Dec 31, 2025; after Feb 2026 $150M offering net $140.4M, runway through 1H 2028.
- GAAP net loss Q4 2025 ($22.8M)/($0.42) vs ($29.2M)/($0.55) in Q4 2024; full year ($101.7M)/($1.90) vs ($134.9M)/($2.58).
- R&D expenses Q4 2025 $17.6M vs $23.5M in Q4 2024; full year $77.0M vs $116.4M.
- Barbara Klencke appointed permanent CMO; completed $150M registered equity offering in Feb 2026.
- Clinical milestones: evorpacept biomarker data; ASPEN-09 enrollment expanded to 120 pts, topline mid-2027; ALX2004 safety data 2H 2026.

## SEC filing metadata
- accession: 0001193125-26-079342
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000119312526079342/0001193125-26-079342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000119312526079342/alxo-20260227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-079342
- JSON: https://secwatch.observer/filing/0001193125-26-079342.json
- Plain text: https://secwatch.observer/filing/0001193125-26-079342.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.